N-(3,4-dimethylphenyl)-N-methyl-4-oxo-3-(4-phenylpiperazine-1-carbonyl)-1H-quinoline-6-sulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(3,4-dimethylphenyl)-N-methyl-4-oxo-3-(4-phenylpiperazine-1-carbonyl)-1H-quinoline-6-sulfonamide
• 化学式: C₂₉H₃₀N₄O₄S
• 分子量: 530.6
• InChiKey: GUOCLWXSVGOEMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  38
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  98.4
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Fibrosis Inhibiting Compounds and Methods of Use Thereof in the Prevention or Treatment of Fibrosing Diseases
  申请人：Gomer Richard H.

  公开号：US20160272713A1

  公开（公告）日：2016-09-22

  The present disclosure relates to a method of inhibiting fibrocyte or profibrotic macrophage formation by administering a CD209-binding compound or antibody to monocytes in a target location in an amount and for a time sufficient to suppress formation of fibrocytes or profibrotic macrophages from the monocytes. It also relates to compounds and pharmaceutical formulations for use in such methods. The disclosure further relates to compositions usable with these methods and method of detecting CD209-binding compounds and antibodies able to inhibit fibrocyte or profibrotic macrophage formation.

  本公开涉及一种通过向靶位点的单核细胞中投与CD209结合的化合物或抗体来抑制成纤维细胞或促纤维化巨噬细胞形成的方法，所述化合物或抗体的用量和时间足以抑制单核细胞形成成纤维细胞或促纤维化巨噬细胞。此外，本公开还涉及用于这些方法的化合物和制药配方。本公开进一步涉及用于这些方法的组合物以及检测能够抑制成纤维细胞或促纤维化巨噬细胞形成的CD209结合化合物和抗体的方法。
• FIBROSIS INHIBITING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF FIBROSING DISEASES
  申请人：THE TEXAS A&M UNIVERSITY SYSTEM

  公开号：EP3065548B1

  公开（公告）日：2019-08-21
• Compositions Associated with and Methods of Managing Neutrophil Movement
  申请人：Gomer Richard H.

  公开号：US20160208002A1

  公开（公告）日：2016-07-21

  The disclosure also relates to a method of reducing the number of neutrophils in a body region by administering a CD209-binding compound or antibody in an amount and for a time sufficient to suppress neutrophil movement into the body region. In particular, it relates to a method of reducing the number of neutrophils in a body region suffering from an acute injury or from a chronic or long-term disease. The disclosure further relates to compositions usable with these methods and method of detecting CD209-binding compounds and antibodies able to affect neutrophil movement or adhesion.